Intelence (Etravirine, TMC125)

The Basics | News & Research

See also: Medication Side Effects | Drug Interactions | All HIV Medications

Brand Name:	Intelence
Generic Name:	Etravirine, TMC125
Adult Single Dose:	One 200-mg tablet or two 100-mg tablets (twice a day)
Food & Liquid Restrictions:	Take after a meal
Drug Class:	NNRTI

From The Body's "Ask the Experts" Forums

I want to stop taking Fuzeon (enfuvirtide, T-20). Would Intelence and Isentress (raltegravir, MK-0518) be a good alternative?
I have developed resistance to the HIV drugs I'm taking. Eventually I plan to change my regimen and start a regimen with Intelence. Should I make the change immediately, or wait until my CD4 count drops below 300?
I developed a rash after I started taking Intelence. Should I continue taking it?

» More questions

Click here for a summary of the essential details on Intelence (etravirine, TMC125) from Cal Cohen, M.D.

The Basics

Etravirine (Intelence) (March 28, 2012)
To read PDF, click here.
From AIDS InfoNet
An Overview of Intelence (TMC125, Etravirine) (March 27, 2012)
From AIDSinfo
Intelence (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
FAQs About Intelence (Etravirine) (January 3, 2012)
From The Body's "Ask the Experts" Forums
Patient Information About Intelence (TMC125, Etravirine) (PDF) (October 2011)
From Tibotec Therapeutics
HIV/AIDS Update -- New Intelence Labeling: Severe Skin and Hypersensitivity Reactions (August 2009)
Important drug warning.
To read PDF, click here.
From Tibotec Therapeutics
Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
News Analysis: U.S. Approval of Intelence (Etravirine) (January 25, 2008)
An interview with Cal Cohen, M.D., M.S.
From TheBody.com
Project Inform Welcomes Approval and Pricing of Intelence, Calls for Further Research (January 23, 2008)
From Project Inform
Intelence (TMC125, Etravirine) Approved in United States (January 19, 2008)
From U.S. Food and Drug Administration
Intelence (Etravirine) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs

News & Research

Intelence Now for Kids Ages 6 and Older (May/June 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Intelence (Etravirine): Pediatric Dosing Recommendations and New Scored 25 mg Tablet for Pediatric Dosing (March 26, 2012)
From U.S. Food and Drug Administration
Etravirine 200-mg Formulation Available in UK (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Paediatric Antiretroviral Pipeline: Update on Etravirine and Maraviroc (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
MSF Letter Criticizes Johnson & Johnson for Not Joining Medicines Patent Pool (April 26, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
Newly Approved Intelence (Etravirine) Dose May Halve Pill Burden (December 23, 2010)
From U.S. Food and Drug Administration
Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects (July 20, 2010)
From AIDSmeds.com
Intelence (Etravirine) Label Revised to Include New Drug-Drug Interaction Information (March 11, 2010)
From U.S. Food and Drug Administration
New Warning of Serious Intelence Side Effect (February 2010)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
FDA Grants Full Approval to J&J's HIV Drug (December 8, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Intelence (Etravirine) Label Updated to Reflect Dosing Data Through 48 Weeks (November 25, 2009)
From U.S. Food and Drug Administration
Information for Health Care Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Health Care Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC) (November 17, 2009)
From U.S. Food and Drug Administration
Tibotec, FDA Update Warning Label on HIV Drug's Risk of Severe Skin Reaction (August 27, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
New FDA Report Suggests Possible Link Between Intelence and Joint Problems (September 8, 2008)
From Associated Press
AAHIVM Encouraged by TMC125 Approval (January 22, 2008)
New HIV medication could offer more options for treatment-experienced patients.
From American Academy of HIV Medicine
Fair Pricing Coalition Lauds Pricing of New Tibotec Drug (January 21, 2008)
From Fair Pricing Coalition
FDA Receives New Drug Application for TMC125 (Etravirine) (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
The Next HIV Therapies (February 2007)
MK-0518, TMC125 and Maraviroc.
In HIV JournalView, from TheBodyPRO.com
MK-0518 Plus Etravirine? No Problem! (January 5, 2007)
From Project Inform
NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From TheBodyPRO.com
Tibotec Announces Expanded Access Programme for New NNRTI TMC125 (September 26, 2006)
From aidsmap.com
Tibotec Pharmaceuticals Ltd. Announces Expanded Access Program for Its Investigational Agent TMC125 (September 25, 2006)
Program will provide early access for eligible HIV-1-infected patients who have limited treatment options.
From Tibotec Pharmaceuticals Ltd.
NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From TheBody.com
AIDS Activists Urge Tibotec to Expand Access to TMC125, Show Compassion for HIV Salvage Patients (March 8, 2006)
From Salvage Therapies
Behind the December 2004 "AIDS Breakthrough" Headlines (December 31, 2004)
[Archived Article]
Mid-December press reports were exaggerated, but still important; they focus on DAPYs, a promising new family of HIV meds.
In AIDS Treatment News, from AIDS Treatment News
Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
[Archived Article]
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group
Waiting in the Wings: More New Drugs (November/December 2003)
[Archived Article]
A look at 908, TMC-125 and entry inhibitors in development.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
TMC-125: A New NNRTI (March 2002)
[Archived Article]
To read PDF, click here.
In Project Inform Perspective, from Project Inform
TMC125 Monotherapy for 1 Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a Five-Drug Regimen (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
TMC125 Is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
One Week of Monotherapy with TMC-125, a Novel Highly Potent NNRTI, Produces a Mean 2-Log Reduction in Viral Load in Antiretroviral-Naive, HIV-1-Infected Volunteers (October 28, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com